Monday, March 13, 2023 4:40:46 PM
From Revive's patent from March 16th, 2021: "Preliminary indications are that none of the patients receiving Bucillamine in the trial have to date been hospitalised for COVID-19 or have died from COVID-19."
https://www.reddit.com/r/RVVTF/comments/r9ug7u/from_revives_patent_from_march_16th_2021/
However, there's no mention about the 1 placebo death or placebo hospital admissions.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM